John L. Marshall, MD, discusses factors to consider when prescribing third line therapy for colorectal cancer in a discussion with Targeted Oncology.
John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital, professor of medicine and oncology, and director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown-Lombardi Comprehensive Cancer Center, discusses factors to consider when prescribing third line therapy for colorectal cancer in a discussion with Targeted Oncology.
According to Marshall, there are 3 or more medications to choose from when considering third line therapy including regorafenib (Stivarga) and TAS-102 (trifluridine and tipiracil, brand name Lonsurf. This space is also constantly evolving, with promising new combinations from Lonsurf.
It is also important to consider what drugs the patient has been on previously, according to Marshall. All other options, including HER2 should be considered first prior to third line treatment. In summary, it really depends on the patient in front of you. For a patient with a more stable disease, regorafenib may be a good option.
Retrospective Data Highlight Impact of Dose Escalation of Regorafenib in mCRC
May 9th 2024During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that looked at outcomes of dose optimization of regorafenib for patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Read More
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More